Aptamers and their applications in nanomedicine.
暂无分享,去创建一个
[1] L. Gold,et al. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] C. Hong,et al. Magnetic-assisted rapid aptamer selection (MARAS) for generating high-affinity DNA aptamer using rotating magnetic fields. , 2014, ACS combinatorial science.
[3] H. Bermudez,et al. Aptamer-Targeted DNA Nanostructures for Therapeutic Delivery , 2014, Molecular pharmaceutics.
[4] Robert Langer,et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.
[5] F. Lisdat,et al. Properties of an LNA-modified ricin RNA aptamer. , 2012, Biochemical and biophysical research communications.
[6] R. Duncan,et al. Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.
[7] K. Greish,et al. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect , 2014, International journal of nanomedicine.
[8] Brian A. Cohen,et al. Targeted in vitro photodynamic therapy via aptamer-labeled, porphyrin-loaded virus capsids. , 2013, Journal of photochemistry and photobiology. B, Biology.
[9] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[10] Weihong Tan,et al. DNA aptamer–micelle as an efficient detection/delivery vehicle toward cancer cells , 2009, Proceedings of the National Academy of Sciences.
[11] R. Langer,et al. Drug delivery and targeting. , 1998, Nature.
[12] Qingxin Mu,et al. Immunomodulation of Nanoparticles in Nanomedicine Applications , 2014, BioMed research international.
[13] Y. Jeong,et al. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. , 2011, Small.
[14] L. Kèlland,et al. Discovery and development of anticancer aptamers , 2006, Molecular Cancer Therapeutics.
[15] Huan‐Tsung Chang,et al. Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. , 2013, Nanoscale.
[16] Andrew D Ellington,et al. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. , 2002, Nucleic acids research.
[17] S. M. Taghdisi,et al. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer , 2013, Journal of drug targeting.
[18] Tracy K. Pettinger,et al. Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.
[19] Yong Wang,et al. A temperature-responsive antibody-like nanostructure. , 2010, Biomacromolecules.
[20] David D. Smith,et al. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. , 2011, Methods.
[21] Hui Chen,et al. Molecular recognition of acute myeloid leukemia using aptamers , 2008, Leukemia.
[22] T. Minko,et al. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[23] Chun Xing Li,et al. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. , 2013, Small.
[24] J. Kiel,et al. In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. , 1999, Biosensors & bioelectronics.
[25] Soonhag Kim,et al. Bioimaging of targeting cancers using aptamer-conjugated carbon nanodots. , 2013, Chemical communications.
[26] Omid C Farokhzad,et al. Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.
[27] Michael Famulok,et al. Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures , 2010, Nature Protocols.
[28] J. Katzenellenbogen,et al. Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo. , 2013, Journal of materials chemistry. B.
[29] Jian Wang,et al. Photosensitizer-gold nanorod composite for targeted multimodal therapy. , 2013, Small.
[30] Yong Wang,et al. A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. , 2009, Macromolecular bioscience.
[31] Chun-hua Lu,et al. Bioresponsive controlled release using mesoporous silica nanoparticles capped with aptamer-based molecular gate. , 2011, Journal of the American Chemical Society.
[32] Thomas Bair,et al. Rapid Identification of Cell-Specific, Internalizing RNA Aptamers with Bioinformatics Analyses of a Cell-Based Aptamer Selection , 2012, PloS one.
[33] J. Otlewski,et al. Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles , 2013, International journal of nanomedicine.
[34] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[35] Dorma C. Flemister,et al. Selective Light-Triggered Release of DNA from Gold Nanorods Switches Blood Clotting On and Off , 2013, PloS one.
[36] Yinan Zhong,et al. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. , 2014, Biomacromolecules.
[37] Tetsuro Tanaka,et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). , 2004, International journal of pharmaceutics.
[38] Ronghua Yang,et al. Regulation of singlet oxygen generation using single-walled carbon nanotubes. , 2008, Journal of the American Chemical Society.
[39] S. Ryu,et al. Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature , 2013, Nanoscale Research Letters.
[40] M. Avci-Adali,et al. Pitfalls of cell-systematic evolution of ligands by exponential enrichment (SELEX): existing dead cells during in vitro selection anticipate the enrichment of specific aptamers. , 2010, Oligonucleotides.
[41] Xiaoyan Zhu,et al. Investigation on novel chitosan nanoparticle-aptamer complexes targeting TGF-β receptor II. , 2013, International journal of pharmaceutics.
[42] P. Tinnefeld,et al. One-pot synthesized aptamer-functionalized CdTe:Zn2+ quantum dots for tumor-targeted fluorescence imaging in vitro and in vivo. , 2013, Analytical chemistry.
[43] Tao Chen,et al. Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. , 2014, Chemical communications.
[44] Li Tang,et al. Aptamer-functionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors. , 2012, Angewandte Chemie.
[45] Anthony D. Keefe,et al. Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. , 2005, Chemistry & biology.
[46] W. Tan,et al. Aptamers recognizing glycosylated hemagglutinin expressed on the surface of vaccinia virus-infected cells. , 2010, Analytical chemistry.
[47] B. Sullenger,et al. In vivo selection of tumor-targeting RNA motifs , 2009, Nature chemical biology.
[48] R. Duncan. Polymer therapeutics as nanomedicines: new perspectives. , 2011, Current opinion in biotechnology.
[49] John C. Burnett,et al. Current Progress of RNA Aptamer-Based Therapeutics , 2012, Front. Gene..
[50] Jinhui Wu,et al. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. , 2013, Molecular pharmaceutics.
[51] Volker A Erdmann,et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. , 2004, Nucleic acids research.
[52] Xin Li,et al. Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers. , 2003, Nucleic acids research.
[53] Tracy R. Keeney,et al. From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.
[54] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[55] Y. Zu,et al. Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.
[56] Jianjun Cheng,et al. Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide). , 2012, Current opinion in solid state & materials science.
[57] Omid C Farokhzad,et al. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. , 2012, ACS nano.
[58] B. Sullenger,et al. Gene therapy progress and prospects: RNA aptamers , 2007, Gene Therapy.
[59] William H. Thiel,et al. Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells. , 2013, Virology.
[60] Jie Li,et al. Identification of an aptamer targeting hnRNP A1 by tissue slide‐based SELEX , 2009, The Journal of pathology.
[61] Peixuan Guo,et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. , 2005, Human gene therapy.
[62] Peixuan Guo,et al. Thermodynamically Stable RNA three-way junctions as platform for constructing multi-functional nanoparticles for delivery of therapeutics , 2011, Nature Nanotechnology.
[63] Paloma H. Giangrande,et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers , 2012, Nucleic acids research.
[64] Silvia Catuogno,et al. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[65] Kemin Wang,et al. Au@Ag/Au nanoparticles assembled with activatable aptamer probes as smart "nano-doctors" for image-guided cancer thermotherapy. , 2014, Nanoscale.
[66] David E. Smith,et al. Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptide. , 2013, Molecular pharmaceutics.
[67] K. Neoh,et al. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. , 2011, Macromolecular bioscience.
[68] An RNA Alternative to Human Transferrin: A New Tool for Targeting Human Cells , 2012, Molecular therapy. Nucleic acids.
[69] E. Ng,et al. Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases , 2006, Annals of the New York Academy of Sciences.
[70] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.
[71] Prahlad T. Ram,et al. 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity , 2014, Nature Communications.
[72] Anthony D. Keefe,et al. SELEX with modified nucleotides. , 2008, Current opinion in chemical biology.
[73] D. Shangguan,et al. Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.
[74] M. Famulok,et al. Prion‐Protein‐Specific Aptamer Reduces PrPSc Formation , 2002, Chembiochem : a European journal of chemical biology.
[75] Robert Langer,et al. Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy , 2011 .
[76] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[77] V. C. Özalp,et al. Targeting cancer cells with controlled release nanocapsules based on a single aptamer. , 2013, Chemical communications.
[78] S. Klußmann,et al. Spiegelmers: Biostable Aptamers , 2003, Chembiochem : a European journal of chemical biology.
[79] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[80] J. Cheong,et al. Maleimidyl magnetic nanoplatform for facile molecular MRI , 2014, Nanotechnology.
[81] B. Sullenger,et al. Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.
[82] M. Hutmacher,et al. Population Pharmacokinetics of Pegaptanib in Patients With Neovascular, Age‐Related Macular Degeneration , 2012, Journal of clinical pharmacology.
[83] Weihong Tan,et al. Generating aptamers for recognition of virus-infected cells. , 2009, Clinical chemistry.
[84] C. Thaxton,et al. Update on current and potential nanoparticle cancer therapies , 2013, Current opinion in oncology.
[85] John T McDevitt,et al. Aptamer-based sensor arrays for the detection and quantitation of proteins. , 2004, Analytical chemistry.
[86] Kemin Wang,et al. ATP-responsive controlled release system using aptamer-functionalized mesoporous silica nanoparticles. , 2012, Langmuir : the ACS journal of surfaces and colloids.
[87] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[88] Weihong Tan,et al. In vitro Selection of DNA Aptamers to Glioblastoma Multiforme. , 2011, ACS chemical neuroscience.
[89] Peixuan Guo,et al. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. , 2012, Nano today.
[90] Zhi Zhu,et al. Monoclonal surface display SELEX for simple, rapid, efficient, and cost-effective aptamer enrichment and identification. , 2014, Analytical chemistry.
[91] Rebecca Richards-Kortum,et al. Aptamer-Targeted Gold Nanoparticles As Molecular-Specific Contrast Agents for Reflectance Imaging , 2008, Bioconjugate chemistry.
[92] Alfonso Latorre,et al. DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. , 2014, Nanoscale.
[93] A D Ellington,et al. Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.
[94] Q. Ma,et al. A novel aptamer functionalized CuInS2 quantum dots probe for daunorubicin sensing and near infrared imaging of prostate cancer cells. , 2014, Analytica chimica acta.
[95] Dong Liang,et al. Selective Uptake and Imaging of Aptamer- and Antibody-Conjugated Hollow Nanospheres Targeted to Epidermal Growth Factor Receptors Overexpressed in Head and Neck Cancer , 2014, ACS nano.
[96] E. Ng,et al. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[97] Liyu Li,et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. , 2014, Biomaterials.
[98] D. Volk,et al. X-aptamers: a bead-based selection method for random incorporation of druglike moieties onto next-generation aptamers for enhanced binding. , 2012, Biochemistry.
[99] Mohammad Ramezani,et al. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[100] Omid C Farokhzad,et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. , 2012, Chemical Society reviews.
[101] A. Adamis,et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. , 2007, Ophthalmology.
[102] Jian Wang,et al. Aptamer-conjugated nanorods for targeted photothermal therapy of prostate cancer stem cells. , 2013, Chemistry, an Asian journal.
[103] N. Zhao,et al. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma , 2011, Journal of nanobiotechnology.
[104] Amy C Yan,et al. Cell internalization SELEX: in vitro selection for molecules that internalize into cells. , 2014, Methods in molecular biology.
[105] N. Zhao,et al. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. , 2013, Biomaterials.